A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Sponsor
Yonsei University
Study ID
NCT03798106
Phase
PHASE2
Status
Completed

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may warrant further combination.

Key Dates

Start date
Apr 10, 2019
Status verified
Jun 2023
Primary completion
Aug 10, 2022
Completion
Aug 10, 2022

Study Design

Enrollment
46 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: durvalumab+pazopanib
    Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks

Primary Outcome Measure

Objective Response Rate [ Time Frame: 12 weeks ]

Related Studies